Author

Prakash Packrisamy

University of Nebraska–LincolnORCID 0009-0003-2404-5561Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:benchmark study· 1 Research Focus:benchmarking· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:large language model· 1

Frequent Co-Authors

Ahmed Abdeen HamediD· 2 shared Tomáš HelikariD· 2 shared Bhanwar Lal PuniyaiD· 1 shared Frank Agayie-NtimiD· 1 shared Josh LoeckeriD· 1 shared Lindsey B. CrawfordiD· 1 shared Narayana Pujara· 1 shared ROBERT E. MOOREiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

9 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Ahmed Abdeen HamedORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systems BiologybioRxivPreprintJul 22, 2026

MechAInistic: An LLM-guided Multi-Agent System for Reasoning over Genome-Scale Constraint-Based Metabolic Models

Josh Loecker, Narayana Pujara, William Bryant…·Tomáš Helikar

MechAInistic uses a multi-agent system guided by LLMs to generate auditable hypotheses from genome-scale metabolic models, identifying potential drug targets and metabolic rewiring in disease states.

DOI 10.64898/2026.05.11.723319

metabolomicsdeep learning

𝕏 PostBluesky

BioinformaticsbioRxivPreprintJun 5, 2026

MarkerScout: A Disease-Agnostic Machine Learning Framework for Biomarker Prediction from Multi-Scale Mechanistic Models

ROBERT E. MOORE, Frank Agayie-Ntim, Lindsey B. Crawford…·Tomáš Helikar

MarkerScout ranks biomarkers across clinical phases using a disease-agnostic framework with cross-validated F1 scores above 0.99 and direction-aware tiers.

DOI 10.64898/2026.05.30.727266

humanproteomics

𝕏 PostBluesky